Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.35, while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QYLD | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $6.79 |
52-Week Low | $16.70 | $2.84 |
Market Cap | — | $1.74B |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.37, up 0.05% with a bullish technical signal from moving averages. The ETF generates income through covered calls on the NASDAQ-100, providing an estimated 11-12% yield but limiting upside participation in strong bull markets. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income generation while the underlying index experiences volatility.
The outlook remains mixed - QYLD offers attractive monthly income for retirees but has historically underperformed the NASDAQ-100 during sustained rallies. Principal erosion risk exists as the strategy caps gains during market advances. Investors should weigh high yield against potential long-term capital appreciation sacrifice in tech-heavy markets.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
